You are here

lung cancer

Mirati's long wait for next lung cancer med ends in phase 3 failure

Mirati's long wait for next lung cancer med ends in phase 3 failure

Fierce Biotech

Mirati Therapeutics

clinical trials

non small cell lung cancer

Flag link:

Mirati's KRAS drug beats estimates in Q1, but Keytruda combo plan remains unclear

Mirati's KRAS drug beats estimates in Q1, but Keytruda combo plan remains unclear

Fierce Pharma

Mirati Therapeutics

Flag link:

Scorpion snags $553M deal with Pierre Fabre for 2 preclinical lung cancer assets

Scorpion snags $553M deal with Pierre Fabre for 2 preclinical lung cancer assets

Fierce Biotech

Scorpion Therapeutics

Flag link:

Lazertinib and Tagrisso go head to head

Lazertinib and Tagrisso go head to head

EP Vantage

Flag link:

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases

CP WIre

Bristol Myers Squibb

executive compensation

Flag link:

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases

Bristol Myers Squibb

executive compensation

Flag link:

AstraZeneca says cancer drug Imfinzi improves survival chances in late-stage trial

AstraZeneca says cancer drug Imfinzi improves survival chances in late-stage trial

Reuters

Flag link:

Tagrisso reaches OS endpoint in PhIII EGFR-mutated lung cancer trial

Tagrisso reaches OS endpoint in PhIII EGFR-mutated lung cancer trial

Endpoints

clinical trials

Flag link:

Merck reports two Phase 3 study misses for Keytruda

Merck reports two Phase 3 study misses for Keytruda

BioPharma Dive

clinical trials

prostate cancer

Flag link:

Novocure shares soar on positive lung cancer data

Novocure shares soar on positive lung cancer data

BioPharma Dive

clinical trials

Flag link:

Despite Imfinzi fail in lung cancer trial, AZ 'encouraged' by one result: exec

Despite Imfinzi fail in lung cancer trial, AZ 'encouraged' by one result: exec

Fierce Pharma

non-small cell lung cancer

Flag link:

FDA Approval of Mirati Lung Cancer Drug Sets Stage for Competition With Amgen

FDA Approval of Mirati Lung Cancer Drug Sets Stage for Competition With Amgen

MedCity News

Mirati Therapeutics

Flag link:

Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients

Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients

Yahoo/Reuters

Mirati Therapeutics

metastatic lung cancer

Flag link:

NanOlogy concludes subject enrolment in Phase IIa lung cancer trial

NanOlogy concludes subject enrolment in Phase IIa lung cancer trial

Clinical Trials Arena

clinical trials

microparticle paclitaxel

Flag link:

FDA explains why it won't pull Jazz's accelerated approval despite a failed confirmatory trial

FDA explains why it won't pull Jazz's accelerated approval despite a failed confirmatory trial

Endpoints

Jazz Pharmaceuticals

metastatic small cell lung cancer

Flag link:

4 Biotech Stocks With Huge Incoming Catalysts

4 Biotech Stocks With Huge Incoming Catalysts

Motley Fool

Alzheimer's disease

Gilead Sciences

Mirati Therapeutics

Flag link:

GSK hits go on pivotal TIM-3 lung cancer trial after phase 2 clears bar for advancement

GSK hits go on pivotal TIM-3 lung cancer trial after phase 2 clears bar for advancement

Fierce Biotech

clinical trials

non-small cell lung cancer

Flag link:

ESMO: Amgen's Lumakras confirmatory lung cancer data are here, fanning KRAS battle flames

ESMO: Amgen's Lumakras confirmatory lung cancer data are here, fanning KRAS battle flames

Fierce Pharma

KRAS inhibitors

Flag link:

Jounce’s latest setback dampens outlook for another cancer immunotherapy target

Jounce’s latest setback dampens outlook for another cancer immunotherapy target

BioPharma Dive

Jounce Therapeutics

cancer immunotherapy

Flag link:

Novartis bid to repurpose rare disease drug for cancer falls short in third trial

Novartis bid to repurpose rare disease drug for cancer falls short in third trial

BioPharma Dive

clinical trials

Flag link:

Pages